Loading
PB
PharmaCyte Biotech, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 07 Jan 2026.
PharmaCyte Biotech, Inc.: what insiders have been doing
PharmaCyte Biotech, Inc. is a listed company. Its insiders report their share dealings to SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 7 filings came from 5 insiders.
Only purchases show up on the open market, 2 purchases in all worth €33k, filed by 2 insiders. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Biggest ticket of the year: €20k, bought by Silverman Joshua and made public on 7 January 2026. The buyers include 1 senior executive and 1 chief executive.
In the case of 2 purchases, another manager of the company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The last insider purchase was made public on 7 January 2026, 284 days ago.
With 7 filings in twelve months, the company is quieter than the median of 19 filings across the 5,813 companies we follow on the same exchange. Over the whole record (from 2025), the tally stands at 2 purchases and no sales.
Other companies in the same market with recent insider buying flagged by our signals: GameStop Corp. and Heico Corp. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
7
Thresholds
n/a
Buy Volume
€33,358
2 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleJonathan Schechter1 buy
Joshua Silverman1 buy
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Last declaration on 7 January 2026
Declarations7 total
30,000 shares@ US$0.7831100.0% of flowCommon StockSEC:0001683168-26-000148:0
Canonical exit: 5 Apr 2026 (T+90)
20,000 shares@ US$0.7776100.0% of flowCommon StockSEC:0001683168-26-000147:0
Canonical exit: 5 Apr 2026 (T+90)
75,000 shares0Common StockSEC:0001683168-25-009116:0
37,500 shares0Common StockSEC:0001683168-25-009115:0
575,000 shares0Common StockSEC:0001683168-25-009114:0
37,500 shares0Common StockSEC:0001683168-25-009112:0
150,000 shares0Common StockSEC:0001683168-25-009113:0
7 of 7 declarations
About PharmaCyte Biotech, Inc.
PharmaCyte Biotech, Inc. is a biopharmaceutical company focused on developing treatments for cancer and other serious diseases. It utilizes a stem cell technology to create innovative therapies.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
